Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Summary

The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.

Timeline

Start

2022-06-30

Primary completion

2024-04-26

Completion

2024-04-26

Outcome

Met primary endpoint

release “Data received from the phase III trial met primary endpoint as well as key secondary endpoints.” harbourbiomed.com ↗

release “Data from the trial met the primary endpoint as well as key secondary endpoints.” hanall.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Batoclimab	Monoclonal antibody	680 mg	Subcutaneous

Indications